Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma. // Seminars in Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0093775426001156?dgcid=rss_sd_all
Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma. Seminars in Oncology. https://www.sciencedirect.com/science/article/pii/S0093775426001156?dgcid=rss_sd_all
“Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma.” Seminars in Oncology.
@article{article65792,
title = {Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma},
journal = {Seminars in Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0093775426001156?dgcid=rss_sd_all}
}
ABSTRACT Diagnosing and classifying platelet disorders (PD) is challenging in children. Therefore, we evaluated clinical, laboratory, and genetic data to improve current algorithms by performing a prospective observational cohort study...
Abstract Background and Objectives Perioperative blood transfusion in hip arthroplasty is associated with increased morbidity, prolonged hospitalization, and higher costs. This study aimed to identify independent risk factors and...